Pfizer Limited declared a dividend of ₹75 per equity share for the financial year ended March 31, 2026, during its 75th Annual General Meeting (AGM) held on July 28, 2026. The virtual meeting, conducted via Video Conferencing and Other Audio-Visual Means, also approved the re-appointment of P. Rengan as a Director and ratified the remuneration of its cost auditors for the upcoming fiscal year.

The proceedings were filed with the BSE and NSE pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 3.00 p.m. IST and concluded at 5.17 p.m. IST. Pradip Shah, Chairman and Non-Independent Non-Executive Director, chaired the session from the company’s registered office in Mumbai. Ms. Meenakshi Nevatia, Managing Director, presented an overview of the company’s performance, financial highlights, new product introductions, and key future focus areas to the members.

Key Resolutions Passed

Shareholders approved three ordinary resolutions under ordinary business and one special business item. The dividend declaration represents a significant return to shareholders for FY26. Additionally, the board sought and received approval for the continuation of key governance roles.

The re-appointment of Mr. P. Rengan (DIN: 10362899) ensures continuity in the board’s oversight of plant operations. Under special business, shareholders ratified the remuneration payable to M/s. Kishore Bhatia & Associates, Cost Accountants, for the financial year ending March 31, 2027.

Governance and Procedural Compliance

The meeting adhered to guidelines issued by the Ministry of Corporate Affairs and SEBI regarding virtual gatherings. As the event was conducted without physical presence, the proxy facility was not provided. Instead, members utilized remote e-voting facilities available prior to the meeting, with an additional e-voting window open for 15 minutes post-conclusion. Mr. Nrupang B. Dholakia, Managing Partner of Dholakia & Associates LLP, served as the Scrutinizer for both remote and live e-voting processes.

Statutory Auditors, Secretarial Auditor, and Cost Auditor attended via video conference. Their reports contained no qualifications or adverse remarks and were taken as read with member consent. The Chairman noted that electronic copies of the Annual Report for FY26 had been circulated, with physical copies sent upon request.

What the Numbers Show

The declaration of a ₹75 dividend per share underscores Pfizer’s commitment to shareholder returns despite broader market uncertainties. While specific revenue or profit figures were not detailed in the AGM proceedings, the approval of this dividend amount indicates strong cash flow generation and confidence in the company’s financial health for FY26. The retention of key directors and cost auditors further signals stability in corporate governance structures.

Pfizer reported a year-on-year increase in net profit for the quarter ended June 30, 2026 (Q1FY27), rising 6.6% to ₹204.47 crore from ₹191.75 crore in the corresponding period last year. The pharmaceutical company’s revenue from operations grew 8.3% to ₹653.17 crore, supported by an expansion in EBITDA margin to 37.9% from 34.83%. The results reflect improved operational leverage and cost management during the quarter.

The Board of Directors approved the unaudited financial results at a meeting held on July 28, 2026. The figures were reviewed by the Audit Committee and subsequently limited-reviewed by the statutory auditors, B S R & Co. LLP, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates in a single segment, Pharmaceuticals, and has no subsidiaries or joint ventures as of June 30, 2026.

Revenue and Profitability Performance

Pfizer’s revenue from operations stood at ₹653.17 crore in Q1FY27, compared to ₹603.05 crore in Q1FY26. Other income declined to ₹44.84 crore from ₹67.17 crore in the prior year period, resulting in total income of ₹698.01 crore against ₹670.22 crore previously.

EBITDA for the quarter was ₹246.15 crore (derived from profit before tax and exceptional items plus depreciation and finance costs), up from ₹210.14 crore in Q1FY26. The EBITDA margin expanded significantly to 37.9% from 34.83%, indicating stronger operating efficiency despite higher material costs.

Net Profit and Taxation

Net profit for the quarter increased to ₹204.47 crore from ₹191.75 crore in Q1FY26. Profit before tax rose to ₹276.68 crore from ₹259.53 crore. Tax expense for the quarter was ₹72.21 crore (current tax ₹70.93 crore and deferred tax ₹1.28 crore), compared to ₹67.78 crore in the previous year.

Earnings per share (basic and diluted) grew 6.6% to ₹44.69 per share from ₹41.91 per share in Q1FY26. The company’s paid-up equity share capital remained unchanged at ₹45.75 crore.

What the Numbers Show

The divergence between revenue growth (8.3%) and net profit growth (6.6%) suggests that while top-line momentum is strong, cost pressures partially offset margin gains. However, the significant expansion in EBITDA margin (+307 basis points) indicates that operational efficiencies—likely in employee benefits and other expenses—are driving profitability more than volume growth alone. The decline in other income (from ₹67.17 crore to ₹44.84 crore) highlights that core operational performance is now the primary driver of earnings, reducing reliance on non-operating income streams.